Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

BOLA (BolA Family Member 3) Deficiency Controls Endothelial Metabolism and Glycine Homeostasis in Pulmonary Hypertension.

Yu Q, Tai YY, Tang Y, Zhao J, Negi V, Culley MK, Pilli J, Sun W, Brugger K, Mayr J, Saggar R, Saggar R, Wallace WD, Ross DJ, Waxman AB, Wendell SG, Mullett SJ, Sembrat J, Rojas M, Khan OF, Dahlman JE, Sugahara M, Kagiyama N, Satoh T, Zhang M, Feng N, Gorcsan J 3rd, Vargas SO, Haley KJ, Kumar R, Graham BB, Langer R, Anderson DG, Wang B, Shiva S, Bertero T, Chan SY.

Circulation. 2019 May 7;139(19):2238-2255. doi: 10.1161/CIRCULATIONAHA.118.035889.

PMID:
30759996
2.

The Role of Type 2 Inflammation in Schistosoma-Induced Pulmonary Hypertension.

Mickael CS, Graham BB.

Front Immunol. 2019 Jan 24;10:27. doi: 10.3389/fimmu.2019.00027. eCollection 2019. Review.

3.

Systems Analysis of the Human Pulmonary Arterial Hypertension Lung Transcriptome.

Stearman RS, Bui QM, Speyer G, Handen A, Cornelius AR, Graham BB, Kim S, Mickler EA, Tuder RM, Chan SY, Geraci MW.

Am J Respir Cell Mol Biol. 2019 Jun;60(6):637-649. doi: 10.1165/rcmb.2018-0368OC.

PMID:
30562042
4.

Common genetic variants in pulmonary arterial hypertension.

Gu S, Kumar R, Lee MH, Mickael C, Graham BB.

Lancet Respir Med. 2019 Mar;7(3):190-191. doi: 10.1016/S2213-2600(18)30448-X. Epub 2018 Dec 5. No abstract available.

5.

Comparing pulmonary hypertension severity between rat strains suggests right ventricle NK cells are protective.

Mickael C, Lee MH, Gu S, Graham BB.

Cardiovasc Res. 2019 Mar 15;115(4):699-700. doi: 10.1093/cvr/cvy299. No abstract available.

PMID:
30517607
6.

Paclitaxel blocks Th2-mediated TGF-β activation in Schistosoma mansoni-induced pulmonary hypertension.

Kassa B, Mickael C, Kumar R, Sanders L, Koyanagi D, Hernandez-Saavedra D, Tuder RM, Graham BB.

Pulm Circ. 2019 Jan-Mar;9(1):2045894018820813. doi: 10.1177/2045894018820813. Epub 2018 Dec 4.

7.

Finding the Target: In Silico and Genetic Screening for Mechanistically Novel Drugs in Pulmonary Arterial Hypertension.

Graham BB, Yu PB.

Am J Respir Crit Care Med. 2019 Jan 1;199(1):9-11. doi: 10.1164/rccm.201808-1427ED. No abstract available.

PMID:
30130137
8.

NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Samokhin AO, Stephens T, Wertheim BM, Wang RS, Vargas SO, Yung LM, Cao M, Brown M, Arons E, Dieffenbach PB, Fewell JG, Matar M, Bowman FP, Haley KJ, Alba GA, Marino SM, Kumar R, Rosas IO, Waxman AB, Oldham WM, Khanna D, Graham BB, Seo S, Gladyshev VN, Yu PB, Fredenburgh LE, Loscalzo J, Leopold JA, Maron BA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaap7294. doi: 10.1126/scitranslmed.aap7294.

9.

Vascular Adaptation of the Right Ventricle in Experimental Pulmonary Hypertension.

Graham BB, Kumar R, Mickael C, Kassa B, Koyanagi D, Sanders L, Zhang L, Perez M, Hernandez-Saavedra D, Valencia C, Dixon K, Harral J, Loomis Z, Irwin D, Nemkov T, D'Alessandro A, Stenmark KR, Tuder RM.

Am J Respir Cell Mol Biol. 2018 Oct;59(4):479-489. doi: 10.1165/rcmb.2018-0095OC.

PMID:
29851508
10.

Urocortin 2: will a drug targeting both the vasculature and the right ventricle be the future of pulmonary hypertension therapy?

Stenmark KR, Graham BB.

Cardiovasc Res. 2018 Jul 1;114(8):1057-1059. doi: 10.1093/cvr/cvy117. No abstract available.

PMID:
29800416
11.

Dominant Role for Regulatory T Cells in Protecting Females Against Pulmonary Hypertension.

Tamosiuniene R, Manouvakhova O, Mesange P, Saito T, Qian J, Sanyal M, Lin YC, Nguyen LP, Luria A, Tu AB, Sante JM, Rabinovitch M, Fitzgerald DJ, Graham BB, Habtezion A, Voelkel NF, Aurelian L, Nicolls MR.

Circ Res. 2018 Jun 8;122(12):1689-1702. doi: 10.1161/CIRCRESAHA.117.312058. Epub 2018 Mar 15.

12.

Dynamic and diverse changes in the functional properties of vascular smooth muscle cells in pulmonary hypertension.

Stenmark KR, Frid MG, Graham BB, Tuder RM.

Cardiovasc Res. 2018 Mar 15;114(4):551-564. doi: 10.1093/cvr/cvy004.

13.

Enhanced inflammatory cell profiles in schistosomiasis-induced pulmonary vascular remodeling.

Ali Z, Kosanovic D, Kolosionek E, Schermuly RT, Graham BB, Mathie A, Butrous G.

Pulm Circ. 2017 Apr 4;7(1):244-252. doi: 10.1086/690687. eCollection 2017 Mar.

14.

TGF-β activation by bone marrow-derived thrombospondin-1 causes Schistosoma- and hypoxia-induced pulmonary hypertension.

Kumar R, Mickael C, Kassa B, Gebreab L, Robinson JC, Koyanagi DE, Sanders L, Barthel L, Meadows C, Fox D, Irwin D, Li M, McKeon BA, Riddle S, Dale Brown R, Morgan LE, Evans CM, Hernandez-Saavedra D, Bandeira A, Maloney JP, Bull TM, Janssen WJ, Stenmark KR, Tuder RM, Graham BB.

Nat Commun. 2017 May 30;8:15494. doi: 10.1038/ncomms15494.

15.

A Time- and Compartment-Specific Activation of Lung Macrophages in Hypoxic Pulmonary Hypertension.

Pugliese SC, Kumar S, Janssen WJ, Graham BB, Frid MG, Riddle SR, El Kasmi KC, Stenmark KR.

J Immunol. 2017 Jun 15;198(12):4802-4812. doi: 10.4049/jimmunol.1601692. Epub 2017 May 12.

16.

Right Ventricle Vasculature in Human Pulmonary Hypertension Assessed by Stereology.

Graham BB, Koyanagi D, Kandasamy B, Tuder RM.

Am J Respir Crit Care Med. 2017 Oct 15;196(8):1075-1077. doi: 10.1164/rccm.201702-0425LE. No abstract available.

17.

Fatty Acid Metabolism, Bone Morphogenetic Protein Receptor Type 2, and the Right Ventricle.

Graham BB, Robinson JC, Tuder RM.

Am J Respir Crit Care Med. 2016 Sep 15;194(6):655-6. doi: 10.1164/rccm.201603-0592ED. No abstract available.

18.

Increased mitochondrial arginine metabolism supports bioenergetics in asthma.

Xu W, Ghosh S, Comhair SA, Asosingh K, Janocha AJ, Mavrakis DA, Bennett CD, Gruca LL, Graham BB, Queisser KA, Kao CC, Wedes SH, Petrich JM, Tuder RM, Kalhan SC, Erzurum SC.

J Clin Invest. 2016 Jul 1;126(7):2465-81. doi: 10.1172/JCI82925. Epub 2016 May 23.

19.

Matrix Remodeling Promotes Pulmonary Hypertension through Feedback Mechanoactivation of the YAP/TAZ-miR-130/301 Circuit.

Bertero T, Cottrill KA, Lu Y, Haeger CM, Dieffenbach P, Annis S, Hale A, Bhat B, Kaimal V, Zhang YY, Graham BB, Kumar R, Saggar R, Saggar R, Wallace WD, Ross DJ, Black SM, Fratz S, Fineman JR, Vargas SO, Haley KJ, Waxman AB, Chau BN, Fredenburgh LE, Chan SY.

Cell Rep. 2015 Nov 3;13(5):1016-32. doi: 10.1016/j.celrep.2015.09.049. Epub 2015 Oct 22.

20.

The Causal Role of IL-4 and IL-13 in Schistosoma mansoni Pulmonary Hypertension.

Kumar R, Mickael C, Chabon J, Gebreab L, Rutebemberwa A, Garcia AR, Koyanagi DE, Sanders L, Gandjeva A, Kearns MT, Barthel L, Janssen WJ, Mauad T, Bandeira A, Schmidt E, Tuder RM, Graham BB.

Am J Respir Crit Care Med. 2015 Oct 15;192(8):998-1008. doi: 10.1164/rccm.201410-1820OC.

21.

Severe pulmonary hypertension is associated with altered right ventricle metabolic substrate uptake.

Graham BB, Kumar R, Mickael C, Sanders L, Gebreab L, Huber KM, Perez M, Smith-Jones P, Serkova NJ, Tuder RM.

Am J Physiol Lung Cell Mol Physiol. 2015 Sep 1;309(5):L435-40. doi: 10.1152/ajplung.00169.2015. Epub 2015 Jun 26.

22.

Genetic and hypoxic alterations of the microRNA-210-ISCU1/2 axis promote iron-sulfur deficiency and pulmonary hypertension.

White K, Lu Y, Annis S, Hale AE, Chau BN, Dahlman JE, Hemann C, Opotowsky AR, Vargas SO, Rosas I, Perrella MA, Osorio JC, Haley KJ, Graham BB, Kumar R, Saggar R, Saggar R, Wallace WD, Ross DJ, Khan OF, Bader A, Gochuico BR, Matar M, Polach K, Johannessen NM, Prosser HM, Anderson DG, Langer R, Zweier JL, Bindoff LA, Systrom D, Waxman AB, Jin RC, Chan SY.

EMBO Mol Med. 2015 Jun;7(6):695-713. doi: 10.15252/emmm.201404511.

23.

Schistosomiasis and the pulmonary vasculature (2013 Grover Conference series).

Graham BB, Kumar R.

Pulm Circ. 2014 Sep;4(3):353-62. doi: 10.1086/675983. Review.

24.

Rtp801 suppression of epithelial mTORC1 augments endotoxin-induced lung inflammation.

Nadon AM, Perez MJ, Hernandez-Saavedra D, Smith LP, Yang Y, Sanders LA, Gandjeva A, Chabon J, Koyanagi DE, Graham BB, Tuder RM, Schmidt EP.

Am J Pathol. 2014 Sep;184(9):2382-9. doi: 10.1016/j.ajpath.2014.06.002. Epub 2014 Jul 9.

25.

Role of vascular endothelial growth factor signaling in Schistosoma-induced experimental pulmonary hypertension.

Chabon JJ, Gebreab L, Kumar R, Debella E, Tanaka T, Koyanagi D, Rodriguez Garcia A, Sanders L, Perez M, Tuder RM, Graham BB.

Pulm Circ. 2014 Jun;4(2):289-99. doi: 10.1086/675992.

26.

The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension.

Robinson JC, Graham BB, Rouault TC, Tuder RM.

Am J Respir Cell Mol Biol. 2014 Dec;51(6):721-9. doi: 10.1165/rcmb.2014-0021TR. Review.

27.

Systems-level regulation of microRNA networks by miR-130/301 promotes pulmonary hypertension.

Bertero T, Lu Y, Annis S, Hale A, Bhat B, Saggar R, Saggar R, Wallace WD, Ross DJ, Vargas SO, Graham BB, Kumar R, Black SM, Fratz S, Fineman JR, West JD, Haley KJ, Waxman AB, Chau BN, Cottrill KA, Chan SY.

J Clin Invest. 2014 Aug;124(8):3514-28. doi: 10.1172/JCI74773. Epub 2014 Jun 24.

28.

Adventitial fibroblasts induce a distinct proinflammatory/profibrotic macrophage phenotype in pulmonary hypertension.

El Kasmi KC, Pugliese SC, Riddle SR, Poth JM, Anderson AL, Frid MG, Li M, Pullamsetti SS, Savai R, Nagel MA, Fini MA, Graham BB, Tuder RM, Friedman JE, Eltzschig HK, Sokol RJ, Stenmark KR.

J Immunol. 2014 Jul 15;193(2):597-609. doi: 10.4049/jimmunol.1303048. Epub 2014 Jun 13.

29.

Functional prostacyclin synthase promoter polymorphisms. Impact in pulmonary arterial hypertension.

Stearman RS, Cornelius AR, Lu X, Conklin DS, Del Rosario MJ, Lowe AM, Elos MT, Fettig LM, Wong RE, Hara N, Cogan JD, Phillips JA 3rd, Taylor MR, Graham BB, Tuder RM, Loyd JE, Geraci MW.

Am J Respir Crit Care Med. 2014 May 1;189(9):1110-20. doi: 10.1164/rccm.201309-1697OC.

30.

Fat and cardiotoxicity in hereditary pulmonary hypertension.

Tuder RM, Robinson JC, Graham BB.

Am J Respir Crit Care Med. 2014 Feb 1;189(3):247-9. doi: 10.1164/rccm.201312-2240ED. No abstract available.

31.

Pathology of pulmonary hypertension.

Tuder RM, Stacher E, Robinson J, Kumar R, Graham BB.

Clin Chest Med. 2013 Dec;34(4):639-50. doi: 10.1016/j.ccm.2013.08.009. Epub 2013 Oct 17. Review.

PMID:
24267295
32.

Updated approach for the assessment of ventilator-associated pneumonia.

Macht M, Robinson JC, Graham BB.

Crit Care Med. 2013 Nov;41(11):2641-2. doi: 10.1097/CCM.0b013e3182a84be1. No abstract available.

33.

Pulmonary veins in the normal lung and pulmonary hypertension due to left heart disease.

Hunt JM, Bethea B, Liu X, Gandjeva A, Mammen PP, Stacher E, Gandjeva MR, Parish E, Perez M, Smith L, Graham BB, Kuebler WM, Tuder RM.

Am J Physiol Lung Cell Mol Physiol. 2013 Nov 15;305(10):L725-36. doi: 10.1152/ajplung.00186.2013. Epub 2013 Sep 13.

34.

Schistosomiasis causes remodeling of pulmonary vessels in the lung in a heterogeneous localized manner: Detailed study.

Kolosionek E, King J, Rollinson D, Schermuly RT, Grimminger F, Graham BB, Morrell N, Butrous G.

Pulm Circ. 2013 Apr;3(2):356-62. doi: 10.4103/2045-8932.114764.

35.

Transforming growth factor-β signaling promotes pulmonary hypertension caused by Schistosoma mansoni.

Graham BB, Chabon J, Gebreab L, Poole J, Debella E, Davis L, Tanaka T, Sanders L, Dropcho N, Bandeira A, Vandivier RW, Champion HC, Butrous G, Wang XJ, Wynn TA, Tuder RM.

Circulation. 2013 Sep 17;128(12):1354-64. doi: 10.1161/CIRCULATIONAHA.113.003072. Epub 2013 Aug 19.

36.

Protective role of IL-6 in vascular remodeling in Schistosoma pulmonary hypertension.

Graham BB, Chabon J, Kumar R, Kolosionek E, Gebreab L, Debella E, Edwards M, Diener K, Shade T, Bifeng G, Bandeira A, Butrous G, Jones K, Geraci M, Tuder RM.

Am J Respir Cell Mol Biol. 2013 Dec;49(6):951-9. doi: 10.1165/rcmb.2012-0532OC.

37.

A sinus venosus atrial septal defect is diagnosed by echocardiography with an unusual bubble study.

Dorosz JL, Fonseca BM, Kay JD, Graham BB, Salcedo EE, Quaife RA.

Echocardiography. 2013 Jul;30(6):E182-3. doi: 10.1111/echo.12191. Epub 2013 Apr 1.

PMID:
23551148
38.

Fasting 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography to detect metabolic changes in pulmonary arterial hypertension hearts over 1 year.

Lundgrin EL, Park MM, Sharp J, Tang WH, Thomas JD, Asosingh K, Comhair SA, DiFilippo FP, Neumann DR, Davis L, Graham BB, Tuder RM, Dostanic I, Erzurum SC.

Ann Am Thorac Soc. 2013 Feb;10(1):1-9. doi: 10.1513/AnnalsATS.201206-029OC.

39.

Deletion of iron regulatory protein 1 causes polycythemia and pulmonary hypertension in mice through translational derepression of HIF2α.

Ghosh MC, Zhang DL, Jeong SY, Kovtunovych G, Ollivierre-Wilson H, Noguchi A, Tu T, Senecal T, Robinson G, Crooks DR, Tong WH, Ramaswamy K, Singh A, Graham BB, Tuder RM, Yu ZX, Eckhaus M, Lee J, Springer DA, Rouault TA.

Cell Metab. 2013 Feb 5;17(2):271-81. doi: 10.1016/j.cmet.2012.12.016.

40.

Modern age pathology of pulmonary arterial hypertension.

Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup M, Grizzle WE, Aldred MA, Cool CD, Tuder RM.

Am J Respir Crit Care Med. 2012 Aug 1;186(3):261-72. doi: 10.1164/rccm.201201-0164OC. Epub 2012 Jun 7.

41.

Significant intrapulmonary Schistosoma egg antigens are not present in schistosomiasis-associated pulmonary hypertension.

Graham BB, Chabon J, Bandeira A, Espinheira L, Butrous G, Tuder RM.

Pulm Circ. 2011 Oct-Dec;1(4):456-61. doi: 10.4103/2045-8932.93544.

42.

Targeting energetic metabolism: a new frontier in the pathogenesis and treatment of pulmonary hypertension.

Tuder RM, Davis LA, Graham BB.

Am J Respir Crit Care Med. 2012 Feb 1;185(3):260-6. doi: 10.1164/rccm.201108-1536PP. Epub 2011 Nov 10.

43.

Schistosomiasis-induced experimental pulmonary hypertension: role of interleukin-13 signaling.

Graham BB, Mentink-Kane MM, El-Haddad H, Purnell S, Zhang L, Zaiman A, Redente EF, Riches DW, Hassoun PM, Bandeira A, Champion HC, Butrous G, Wynn TA, Tuder RM.

Am J Pathol. 2010 Sep;177(3):1549-61. doi: 10.2353/ajpath.2010.100063. Epub 2010 Jul 29.

44.

Pulmonary vascular disease associated with parasitic infection--the role of schistosomiasis.

Kolosionek E, Graham BB, Tuder RM, Butrous G.

Clin Microbiol Infect. 2011 Jan;17(1):15-24. doi: 10.1111/j.1469-0691.2010.03308.x. Review.

45.

Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective.

Graham BB, Bandeira AP, Morrell NW, Butrous G, Tuder RM.

Chest. 2010 Jun;137(6 Suppl):20S-29S. doi: 10.1378/chest.10-0048. Review.

46.

Tracheal Basal cells: a facultative progenitor cell pool.

Cole BB, Smith RW, Jenkins KM, Graham BB, Reynolds PR, Reynolds SD.

Am J Pathol. 2010 Jul;177(1):362-76. doi: 10.2353/ajpath.2010.090870. Epub 2010 Jun 3. Erratum in: Am J Pathol. 2010 Oct;177(4):2145.

47.

[Pathogenesis of pulmonary hypertension].

Graham BB, Tuder RM.

Zhonghua Yi Xue Za Zhi. 2009 Aug 11;89(30):2091-3. Chinese. No abstract available.

PMID:
20058607
48.

Diabetes mellitus does not adversely affect outcomes from a critical illness.

Graham BB, Keniston A, Gajic O, Trillo Alvarez CA, Medvedev S, Douglas IS.

Crit Care Med. 2010 Jan;38(1):16-24. doi: 10.1097/CCM.0b013e3181b9eaa5.

PMID:
19789450
49.

TNFalpha inhibits apoptotic cell clearance in the lung, exacerbating acute inflammation.

Borges VM, Vandivier RW, McPhillips KA, Kench JA, Morimoto K, Groshong SD, Richens TR, Graham BB, Muldrow AM, Van Heule L, Henson PM, Janssen WJ.

Am J Physiol Lung Cell Mol Physiol. 2009 Oct;297(4):L586-95. doi: 10.1152/ajplung.90569.2008. Epub 2009 Jul 31.

50.

Clinical problem-solving. Kiss of death.

Graham BB, Kaul DR, Saint S, Janssen WJ.

N Engl J Med. 2009 Jun 11;360(24):2564-8. doi: 10.1056/NEJMcps0806935. No abstract available. Erratum in: N Engl J Med. 2011 May 26;364(21):2078.

PMID:
19516037

Supplemental Content

Loading ...
Support Center